Enzymatic activation of a new antitumour drug, 5-diethylaminoethylamino-8-hydroxyimidazoacridinone, C-1311, observed after its intercalation into DNA.

@article{Mazerska2001EnzymaticAO,
  title={Enzymatic activation of a new antitumour drug, 5-diethylaminoethylamino-8-hydroxyimidazoacridinone, C-1311, observed after its intercalation into DNA.},
  author={Zofia Mazerska and Jaroslaw Dziegielewski and Jerzy Konopa},
  journal={Biochemical pharmacology},
  year={2001},
  volume={61 6},
  pages={685-94}
}
The imidazoacridinone derivative, C-1311, is a new antitumour agent that exhibits strong antitumour activity against experimental colorectal cancer and has been selected for entry into clinical trial. The compound has previously been shown to have DNA non-covalent binding properties in vitro and to bind irreversibly to DNA of tumour cells. The latter effect has also been observed in a cell-free system, but only in the presence of activated enzymes. The present studies were aimed at finding out… CONTINUE READING

From This Paper

Figures, tables, results, connections, and topics extracted from this paper.
12 Extracted Citations
0 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 12 extracted citations

Similar Papers

Loading similar papers…